GlassScriptPhysician profile
Charles Anthony Cefalu
NPI 1497102008
$1,290.85
in general payments reported to CMS, 2019-2025
11 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Hand Surgery provider received nationally (typical 2025 total: $270).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.50 · 2021: $206 · 2022: $572 · 2023: $22.66 · 2024: $216 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $327.59 | 2022-2025 | |
| Stryker Corporation | $257.71 | 2022-2025 | Variax, Hoffmann |
| Alon Medical Technology | $189.28 | 2024 | |
| Skeletal Dynamics INC | $134.17 | 2021 | |
| Medartis INC. | $94.96 | 2022 | |
| Integra Lifesciences Corporation | $89.53 | 2022 | |
| Medtronic, INC. | $72.24 | 2021 | |
| Depuy Synthes Sales INC. | $66.54 | 2022 | |
| Bioventus LLC | $36.31 | 2024-2025 | Exogen Ultrasound Bone Healing System |
| Si-Bone, INC. | $14.50 | 2020 | |
| Kerecis Limited | $8.02 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Cefalu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.